Analysts expect Bright Minds Biosciences Inc. to report revenue of 0.00 for Q3 22, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q3 22 | Q4 22 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - |
| High Estimate | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Low Estimate | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Bright Minds Biosciences Inc. to report earnings per share of -1.34 for Q3 26, against a range of -1.40 to -1.28. The most recent reported quarter, Q2 26, came in at -0.79, a 6.0% beat against the -0.84 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.12 | 0.01 | -0.30 | -0.54 | -0.43 | -0.71 | -0.79 | - | - | - | - |
| High Estimate | -0.41 | -0.02 | -0.32 | -0.52 | -0.55 | -0.78 | -0.80 | -1.28 | -1.52 | -1.80 | -1.92 |
| Low Estimate | -0.49 | -0.02 | -0.34 | -0.62 | -0.63 | -0.88 | -0.88 | -1.40 | -1.70 | -1.94 | -2.32 |
| Consensus Estimate | -0.45 | -0.02 | -0.33 | -0.57 | -0.59 | -0.83 | -0.84 | -1.34 | -1.61 | -1.87 | -2.12 |